3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
40
Neoplasms, Plasma Cell
5
Neoplasms
5
Recurrence
4
Renal Insufficiency
3
Paraproteinemias
3
Hematologic Diseases
3
Smoldering Multiple Myeloma
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Blood Protein Disorders
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Natural Killer/T-cell Lymphoma
1
Monoclonal Gammopathy of Undetermined Significance
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Plasma Cell
1
Immunoproliferative Disorders
1
Immunoglobulin Light-chain Amyloidosis
1
Hodgkin Disease
1
Cryoglobulinemia, Familial Mixed
1
Interventions
fludarabine phosphate
3
Peripheral Blood Stem Cell Transplantation
3
Epoetin Alfa
3
Darbepoetin alfa
3
Cyclophosphamide
3
Curcumin
3
Whole-Body Irradiation
2
Tacrolimus
2
Mycophenolic Acid
2
Methylprednisolone
2
Filgrastim
2
Cyclosporine
2
Busulfan
2
Biopsy
2
Antilymphocyte Serum
2
pyroxamide
1
piperine
1
liposomal amphotericin B
1
isatuximab
1
ibrutinib
1
ferrous sulfate
1
ferric gluconate
1
aldesleukin
1
Urination
1
Topotecan
1
Tissue Banks
1
Therapeutics
1
Tetradecanoylphorbol Acetate
1
Surveys and Questionnaires
1
Sucrose
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Monoclonal Gammopathy of Undetermined Significance
×
isatuximab
×
Clear all
NCT05114109
2021-11-09
ICE
Assistance Publique - Hôpitaux de Paris
Phase 2
Unknown
21 enrolled